An early-stage cell-therapy company developing therapies for solid tumors, Ares Immunotherapy's lead candidate is a mesothelin specific CAR-T cell. The firm's approach is basically anchored in a platform cellular therapy technology based on the presence of CD26, and the proven ability of these cells to mediate significant tumor regression in multiple forms of malignancy. The firm's first clinical indication is expected to be mesothelioma using CD26+ meso-CAR product. In the judgment of management, the widespread expression of mesothelin in solid tumors potentially could enable the firm to move the same construct forward with a clinical pipeline targeting other malignancies: lung, pancreatic and ovarian.
